At 24 months' follow-up, the only phase 3 randomized clinical trial to directly compare functional and oncologic outcomes between robot-assisted laparoscopic prostatectomy and open radical retropubic ...

According to data from two phase III trials presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium, patients with high-risk prostate cancer had a significantly ...

The presence of scar tissue, periprostatic fibrosis, and inflammation due to previous surgery increases the complexity of some surgical tasks, according to investigators. Undergoing radical ...

The most common surgery for prostate cancer is a radical prostatectomy. This surgery involves taking out the entire prostate gland, some lymph nodes and other nearby tissue, like the seminal vesicles ...

SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the validation of its first multimodal artificial ...

Hearing the words “you have cancer” is uniquely frightening and devastating, and those life-altering words are spoken to ...

Men with localized prostate cancer who delayed having robotic-assisted laparoscopic radical prostatectomy for 6 months or more from biopsy had significant 81% increased odds of biochemical recurrence.

Among men with PSA persistence after radical prostatectomy, a higher preoperative PSA surprisingly was linked to lower mortality. Men with PSA persistence and preoperative PSA >20 ng/mL had 31% lower ...

Adding a surgery-specific module to a perioperative telemedicine programme significantly improved functional outcomes after radical prostatectomy, resulting in better urinary continence, a reduced ...

Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a ...

Levee Medical®, a medical device company focused on improving outcomes for prostate cancer surgery patients, today announced continued progress in the clinical and commercial advancement of its Voro® ...